Literature DB >> 3022846

Biosynthesis of factor XIII B subunit by human hepatoma cell lines.

J A Nagy, P Henriksson, J McDonagh.   

Abstract

The plasma transglutaminase, factor XIIIa (FXIIIa), circulates as a zymogen containing two proteins, A and B, arranged in a noncovalent tetrameric complex, A2B2. Biosynthesis of plasma FXIII has not previously been demonstrated. In the present study, direct evidence has been obtained that two human hepatoma cell lines, Hep G2 and PLC/PRF/5, synthesize and secrete FXIII B protein. Secretion of the B subunit of FXIII by Hep G2 was demonstrated by immunoblotting. De novo synthesis by Hep G2 was confirmed in 35S-methionine-labeled cultures. Radiolabeled conditioned medium was concentrated, mixed (1:1) with purified B protein, and examined by crossed immunoelectrophoresis with antiserum to the B subunit. The single protein precipitin arc of purified B protein comigrated with the radiolabeled FXIII from Hep G2 visualized by autoradiography, indicating both electrophoretic and antigenic identity. The data presented here represent the first demonstrations of biosynthesis of FXIII B protein by any cell type and suggest that the liver is the site of synthesis of FXIII B protein. Further analysis of concentrated Hep G2 serum-free conditioned medium (SFCM) and cell lysate by immunoblotting following nondenaturing agarose gel electrophoresis demonstrated the FXIII A protein as well as the B protein and also revealed synthesis and secretion of the A and B proteins by PLC/PRF/5. Crossed immunoelectrophoresis studies of Hep G2 SFCM and cell lysate suggest that Hep G2 cells also synthesize and secrete the plasma FXIII zymogen. With a specific radioimmunoassay for B protein, FXIII was found in Hep G2 SFCM at approximately 4 ng/mL; with an amplified rocket immunoelectrophoresis technique the level was approximately 5 ng/mL.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3022846

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

2.  Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys.

Authors:  Michael G Dodds; Jennifer E Visich; Paolo Vicini
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

3.  Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.

Authors:  Masayoshi Souri; Shiori Koseki-Kuno; Naoki Takeda; Jay L Degen; Akitada Ichinose
Journal:  Int J Hematol       Date:  2007-12-05       Impact factor: 2.490

4.  Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.

Authors:  Sho Mokuda; Yosuke Murata; Naoya Sawada; Kenichiro Matoba; Akihiro Yamada; Makoto Onishi; Yasuaki Okuda; Kazuo Jouyama; Eiji Sugiyama; Kiyoshi Takasugi
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

Review 5.  Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?

Authors:  Wolfgang Korte
Journal:  J Blood Med       Date:  2014-07-09

Review 6.  Factor XIII Subunit A in the Skin: Applications in Diagnosis and Treatment.

Authors:  Lilla Paragh; Daniel Törőcsik
Journal:  Biomed Res Int       Date:  2017-08-15       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.